secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001847903-23-000187
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Q3 2023 net loss $38.6M; cash $281.3M, SerpinPC data at ASH
--------------------------------------------------------------------

- Cash and investments $281.3M as of Sep 30, 2023; expected to fund operations into 2026.
- Net loss of $38.6M vs $53.9M in Q3 2022; R&D expense $28.2M, down 23% YoY.
- SerpinPC Phase 2a Part 5 data accepted for ASH poster Dec 10; PRESent-2 and PRESent-3 registrational studies ongoing.
- ORX750 (OX2R agonist) preclinical data support best-in-class profile for narcolepsy; IND-enabling studies underway, clinical proof-of-concept data planned for 2024.
- LockBody platform: LB101 (PD-L1xCD47) Phase 1/2a ongoing; LB206 (PD-L1xCD3) development candidate selected in August.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000187/0001847903-23-000187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000187/cnta-20231113.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer